Cargando…
Moss‐made pharmaceuticals: from bench to bedside
Over the past two decades, the moss Physcomitrella patens has been developed from scratch to a model species in basic research and in biotechnology. A fully sequenced genome, outstanding possibilities for precise genome‐engineering via homologous recombination (knockout moss), a certified GMP produc...
Autores principales: | Reski, Ralf, Parsons, Juliana, Decker, Eva L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736463/ https://www.ncbi.nlm.nih.gov/pubmed/26011014 http://dx.doi.org/10.1111/pbi.12401 |
Ejemplares similares
-
Glyco-engineering for biopharmaceutical production in moss bioreactors
por: Decker, Eva L., et al.
Publicado: (2014) -
A gene responsible for prolyl-hydroxylation of moss-produced recombinant human erythropoietin
por: Parsons, Juliana, et al.
Publicado: (2013) -
Process Engineering of Biopharmaceutical Production in Moss Bioreactors via Model-Based Description and Evaluation of Phytohormone Impact
por: Ruiz-Molina, Natalia, et al.
Publicado: (2022) -
O-methylated N-glycans Distinguish Mosses from Vascular Plants
por: Stenitzer, David, et al.
Publicado: (2022) -
High contents of very long-chain polyunsaturated fatty acids in different moss species
por: Beike, Anna K., et al.
Publicado: (2013)